Physician Education: Bridging Clinical Research and Patient Care

CME Webcast

CME Webcast

Please read this page before participating in this activity. At the bottom of the page, click on “I have read these instructions and understand them,” to begin activity.

Please note: Adobe Flash is needed to view webcasts. To download the latest version of Adobe Flash Player, please go to http://get.adobe.com/flashplayer/.

HCV is a LIVER Disease

Author(s): Kenneth E. Sherman, MD, PhD
Airdate: June 28, 2013 (58 minutes, 38 seconds)
CME hours: 0.50 (expires June 28, 2014)
Presented at: Hepatitis C Virus (HCV) Infection: Looking Beyond the Interferon Alfa Era
Co-Chair(s): Robert T Schooley MD, David L Thomas MD, MPH

Grant support:

This activity is funded through independent, educational grants at a national level from commercial organizations that are committed to supporting high-quality continuing medical education (CME). This activity is part of a national effort that includes this and other live CME courses, live course webcasts, Cases on the Web, and Topics in Antiviral Medicine.™ In the interest of an objective, unbiased, balanced, and scientifically rigorous program, the IAS–USA seeks and pools funding from companies with competing products to support the program. These companies have no input into or control over the program content or the selection of faculty. We gratefully acknowledge the support of the companies listed below.

PLATINUM SUPPORTER
AbbVie

SILVER SUPPORTERS
Janssen Therapeutics
Gilead Sciences, Inc
Merck & Co, Inc
Vertex Pharmaceuticals, Inc

CME Information:

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this enduring material for a maximum of 6.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (ie, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.

IAS–USA Board of Directors

Constance A. Benson, MD
Dr Benson has no relevant financial affiliations to disclose. Disclosure information for her spouse, Robert T. Schooley, MD, is indicated below. (Updated 2/4/14)

Peter Cassat, JD
Mr Cassat has no relevant financial affiliations to disclose. (Updated 05/30/12)

Judith S. Currier, MD
Dr Currier has received research grants awarded to the University of California Los Angeles from Merck & Co, Inc. and has served as a consultant to Gilead Sciences, Inc, and ViiV Healthcare. (Updated 2/4/14)

Carlos del Rio, MD
Dr del Rio has no relevant financial affiliations to disclose. (Updated 2/4/14)

Joel E. Gallant, MD, MPH
Dr Gallant has served as a consultant or advisor to Gilead Sciences, Inc, Merck & Co, Inc, Janssen Therapeutics, and Takara Bio Inc; and has received research grants or contracts awarded to his institution from Bristol-Myers Squibb, Gilead Sciences, Inc, Merck & Co, Inc, Sangamo BioSciences, Vertex Pharmaceuticals, Inc, and ViiV Healthcare. (Updated 2/24/14)

Roy M. Gulick, MD, MPH
Dr Gulick serves as a co-investigator on research grants awarded to Weill Cornell Medical College from GlaxoSmithKline/ViiV Healthcare. (Updated 12/02/13)

Donna M. Jacobsen
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 1/28/14)

Douglas D. Richman, MD
Dr Richman has been a consultant to Bristol-Myers Squibb, Chimerix, Gen-Probe, Inc, Gilead Sciences, Inc, Sirenas, Prism and Monogram Biosciences, Inc. He owns stock from Chimerix. (Updated 2/7/14)

Michael S. Saag, MD
Dr Saag has received grants and research support from Abbvie, Boehringer Ingelheim Pharmaceuticals, Inc, Gilead Sciences, Inc, GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Inc, and ViiV Healthcare. (Updated 03/11/14)

Robert T. Schooley, MD
Dr Schooley has received research support from Bristol-Myers Squibb and Boehringer Ingelheim Pharmaceuticals, Inc, and has served as a scientific advisor to CytoDyn and Merck & Co, Inc, as a scientific advisory board member for Gilead Sciences, Inc, GlobeImmune, Inc, and Monogram Biosciences, and as a member of data monitoring committees for Axio and Gilead Sciences, Inc. He has stock in GlobeImmune, Inc. (Updated 2/4/14)

Paul A. Volberding, MD
Dr Volberding has served on scientific advisory boards for Bristol-Myers Squibb and Gilead Sciences, Inc. (Updated 2/4/14)

Course Faculty and Staff:

Dr Schooley has received research support from Boehringer Ingelheim Pharmaceuticals, Inc; has served as a scientific advisor to CytoDyn and Merck & Co, Inc; has served as a scientific advisory board member for Gilead Sciences, Inc, GlobeImmune, Inc, and Monogram Biosciences; and as a member of data monitoring committees for Axio and Gilead Sciences, Inc. He has stocks in GlobeImmune, Inc, and has stock options in Achillion Pharmaceuticals, Inc. (Updated 06/20/13)

Dr Thomas has served as a consultant or advisor to Gilead Sciences, Inc, and Janssen Therapeutics. His institution has received grants from Gilead Sciences, Inc, and Merck & Co, Inc. (Updated 06/10/13)

Dr Kim has received grants and research support from Bristol-Myers Squibb and has served on the advisory board for Abbvie. (Updated 06/20/13)

Dr Kiser has received research support from GlaxoSmithKline, Janssen Therapeutics, Merck & Co, Inc, and Vertex Pharmaceuticals, Inc. (Updated 06/18/13)

Dr Sherman has served as a consultant to Bioline, Kadmon Corporation, MedPace Inc, Merck & Co, Inc, Janssen Therapeutics (formerly Tibotec), and Roche Molecular. His institution has received research support from Anadys Pharmaceuticals, AbbVie, Bristol-Myers Squibb, Genentech Inc, Gilead Sciences, Inc, Merck & Co, Inc, and Vertex Pharmaceuticals, Inc. (Updated 06/12/13)

Dr Sulkowski has served as a consultant or scientific advisor for AbbVie, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Vertex Pharmaceuticals, Inc; and has received research grants awarded to his institution from AbbVie, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, Janssen Therapeutics, Merck & Co, Inc, and Vertex Pharmaceuticals, Inc.  (Updated 06/12/13)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (see above).

Cristin M. Toth, CME Project Manager, has no relevant financial affiliations to disclose. (Updated 10/24/13)

Evaluation and Claim Forms

After viewing this webcast, please submit your evaluation form to claim credit.

Contact Information

If you have any questions about this web-based CME activity, please contact the IAS–USA:
425 California Street
Suite 1450
San Francisco, CA   94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration@iasusa.org